Preclinical Assessment of the Feasibility of Applying Controlled Release Oral Drug Delivery to a Lead Series of Atypical Antipsychotics-Reference-Cited by-同舟云学术

Preclinical Assessment of the Feasibility of Applying Controlled Release Oral Drug Delivery to a Lead Series of Atypical Antipsychotics

Published:2006-04 Issue:4 Volume:95 Page:883-895
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Eichenbaum G.,Pollock-Dove C.,Nguyen J.,Li S.,Evans J.,Borghys H.,Kennis L.,Dong L.,van Osdol W.,Dai W.,Scicinski J.,Chen J.,Xu Y.,Ashton D.,Mackie C.,Megens A.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference36 articles.

1. Nifedipine gastrointestinal therapeutic system in stable angina pectoris. Results of a multicenter open-label crossover comparison with standard nifedipine;Vetrovec;Am J Med,1987

2. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride;Sathyan;Br J Clin Pharmacol,2001

3. Controlled drug delivery: Fundamentals and applications,1987

4. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies;Swanson;Arch Gen Psychiatry,2003

5. Formulation of controlled release microspheres containing nicardipine: The role of pharmacokinetic modeling and computer simulation;Mrhar;Eur J Drug Metab Pharmacokinet,1999

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug;The AAPS Journal;2016-07-12

2. Enabling Discovery Through Leveraging and Miniaturizing Pharmaceutical Principles and Processes;Discovering and Developing Molecules with Optimal Drug-Like Properties;2014-09-27

3. Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the α-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The Rational Use of ex Vivo Intestine to Predict in Vivo Absorption;Drug Metabolism and Disposition;2007-10-11